OncologyConsults



Advances in Soft-Tissue Sarcoma

Presented by the Johns Hopkins University School of Medicine.

Supported by an educational grant from Lilly & Co, Inc.

OVERVIEW
Soft-tissue sarcomas (STSs) are a heterogeneous collection of rare tumors. As such, they can arise within any site of the body, including the extremities, trunk, retroperitoneum, and head and neck. There are over 50 different histological subtypes, which can make accurate diagnosis challenging. STS accounts for about 58% of all sarcomas with the remainder diagnosed as sarcomas of the bone and viscera. Outcomes for patients with STS are poor, and local recurrence and metastases are common. The development of new treatments for patients with STS has been stymied by its rarity, which has a limited the number of clinical trials, trial participants, and new agents. However, recently, 4 new therapies have been approved for treating patients with high-grade STS. This activity will explore the challenges in the current care of patients with STS and prospects for improved, more personalized therapy approaches in the future.

GOAL
The goal of this activity is to provide oncology healthcare providers with knowledge that can be applied to developing a treatment plan for their patients with STS.

TARGET AUDIENCE
This activity is intended for oncology healthcare providers who care for patients with STS. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  • IDENTIFY clinical and pathological characteristics of STS and challenges of traditional treatment strategies.
  • EVALUATE the efficacy and safety of first-line STS treatments, including recent changes to clinical practice guidelines.
  • DESIGN a treatment plan for second-line STS therapy, incorporating newly approved agents utilized in various subtypes of STS.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

CME INFORMATION
Accreditation Statement accme_logo The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement — The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. After reviewing this online activity, participants may receive a certificate by receiving a score of 70% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.

The estimated time to complete this activity: 60 minutes.

Release date: December 15, 2017    Expiration date: December 15, 2018

Policy on Speaker and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the instructional materials.

Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:

The following relationships have been reported for this activity:

Planner Disclosures
Dr. Ettinger reports serving as a principal investigator for Golden Biotechnology Corp; serving as a consultant for AbbVie Inc, BeyondSpring Pharmaceuticals, Inc, Boehringer-Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono Inc, Guardant Health Inc, Genentech Inc, Helsinn Therapeutics Inc, Herron Therapeutics, and sanofi-aventis, US LLC.

Dr Ahuja reports serving as a contracted researcher for Astex Pharmaceuticals and Cepheid; serving as a consultant for Johnson & Johnson; and for licensed biomarkers for Cepheid.

No other planners or faculty have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

FACULTY
Chair and Planner
David S. Ettinger, MD

Alex Grass Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Faculty Authors
Nita Ahuja, MD

Professor of Surgery, Oncology, and Urology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Chung-Shien Lee, PharmD, BCPS, BCOP
Assistant Clinical Professor
Department of Clinical Pharmacy Practice
St. John’s University
College of Pharmacy and Health Sciences
Queens, New York

Bradley N. Reames, MD, MS
Complex General Surgical Oncology Fellow
Department of Surgery
Johns Hopkins Hospital
Baltimore, Maryland

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

For CME questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu.
Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY INSTRUCTIONS
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME post-test and evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity.

Preassessment

Advances in Soft Tissue Sarcoma

Nita Ahuja, MD, Chung-Shien Lee, PharmD, BCPS, BCOP , and Bradley N. Reames, MD, MS

Postassessment and Evaluation

This activity was developed in collaboration with ASiM.